|From: NetworkNewsWire (Rep: 0)||Date: 08/15/2019 16:14|
|Forum: Penny Stocks - Msg #3570 - List LXRP msgs ||Thread #674094940 (Rec: 0) |
|NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Four New Patents, Increasing Total Granted to 15|
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the granting of four of its pending patent applications via its wholly-owned subsidiary Poviva Corp. According to the update, the new patents cover delivery of cannabinoids such as THC and CBD, NSAIDs such as ibuprofen, nicotine, and vitamins. With issuance of these four patents, Lexaria’s total patents granted has increased to 15, with eight in the US and seven in Australia, and the company has roughly 60 patent applications pending throughout the world. Lexaria is one of the most patent-rich firms in the Western World for effective blood plasma delivery of cannabis-related compounds in the cannabis or hemp industries with 15 patents already granted for the delivery of cannabinoids.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.